389 related articles for article (PubMed ID: 30518307)
21. Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study.
Tang W; Fan X; Wang L; Hu J
Medicine (Baltimore); 2015 Apr; 94(15):e706. PubMed ID: 25881847
[TBL] [Abstract][Full Text] [Related]
22. FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia.
Westhus J; Noppeney R; Dührsen U; Hanoun M
Leuk Lymphoma; 2019 Apr; 60(4):1014-1022. PubMed ID: 30277107
[TBL] [Abstract][Full Text] [Related]
23. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
Burnett AK; Russell NH; Hills RK; Hunter AE; Kjeldsen L; Yin J; Gibson BE; Wheatley K; Milligan D
J Clin Oncol; 2013 Sep; 31(27):3360-8. PubMed ID: 23940227
[TBL] [Abstract][Full Text] [Related]
24. [IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].
Qian SX; Li JY; Wu HX; Zhang R; Hong M; Xu W; Qiu HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):464-7. PubMed ID: 19379589
[TBL] [Abstract][Full Text] [Related]
25. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Kato K; Yoshida N; Matsumoto K; Matsuyama T
Pediatr Blood Cancer; 2014 Apr; 61(4):712-6. PubMed ID: 24376191
[TBL] [Abstract][Full Text] [Related]
26. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML.
Steinmetz HT; Schulz A; Staib P; Scheid C; Glasmacher A; Neufang A; Franklin J; Tesch H; Diehl V; Dias Wickramanayake P
Ann Hematol; 1999 Sep; 78(9):418-25. PubMed ID: 10525830
[TBL] [Abstract][Full Text] [Related]
27. Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia.
Shargian-Alon L; Wolach O; Rozovski U; Yahav D; Sela-Navon M; Rubinstein M; Oniashvilli N; Pasvolsky O; Raanani P; Yeshurun M
Ann Hematol; 2020 Dec; 99(12):2939-2945. PubMed ID: 32892274
[TBL] [Abstract][Full Text] [Related]
28. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
29. A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
Martínez Sánchez MP; Megías-Vericat JE; Rodríguez-Veiga R; Vives S; Bergua JM; Torrent A; Suárez-Varela S; Boluda B; Martínez-López J; Cano-Ferri I; Acuña-Cruz E; Torres-Miñana L; Martín-Herreros B; Serrano A; Sempere A; Barragán E; Sargas C; Sanz M; Martínez-Cuadrón D; Montesinos P;
Ann Hematol; 2021 Jun; 100(6):1497-1508. PubMed ID: 33914097
[TBL] [Abstract][Full Text] [Related]
30. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
Virchis A; Koh M; Rankin P; Mehta A; Potter M; Hoffbrand AV; Prentice HG
Br J Haematol; 2004 Jan; 124(1):26-32. PubMed ID: 14675405
[TBL] [Abstract][Full Text] [Related]
31. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F
Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
[TBL] [Abstract][Full Text] [Related]
32. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
DiNardo CD; Lachowiez CA; Takahashi K; Loghavi S; Xiao L; Kadia T; Daver N; Adeoti M; Short NJ; Sasaki K; Wang S; Borthakur G; Issa G; Maiti A; Alvarado Y; Pemmaraju N; Montalban Bravo G; Masarova L; Yilmaz M; Jain N; Andreeff M; Jabbour E; Garcia-Manero G; Kornblau S; Ravandi F; Konopleva MY; Kantarjian HM
J Clin Oncol; 2021 Sep; 39(25):2768-2778. PubMed ID: 34043428
[TBL] [Abstract][Full Text] [Related]
33. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
34. Prospective, multicenter, phase II study on reducing the dosage of idarubicin and FLAG for patients younger than 65 years with resistant acute myeloid leukemia: a comparison with a higher dosage trial.
Kim H; Lee JH; Joo YD; Bae SH; Lee JH; Kim DY; Lee WS; Ryoo HM; Jo JC; Park JH; Lee KH
Acta Haematol; 2014; 132(1):87-96. PubMed ID: 24513865
[TBL] [Abstract][Full Text] [Related]
35. Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts.
Reid JH; Perissinotti AJ; Benitez LL; Boyer D; Lee W; Burke PW; Pettit K; Bixby DL; Marini BL
Leuk Res; 2021 Apr; 103():106539. PubMed ID: 33647818
[TBL] [Abstract][Full Text] [Related]
36. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
Parker JE; Pagliuca A; Mijovic A; Cullis JO; Czepulkowski B; Rassam SM; Samaratunga IR; Grace R; Gover PA; Mufti GJ
Br J Haematol; 1997 Dec; 99(4):939-44. PubMed ID: 9432047
[TBL] [Abstract][Full Text] [Related]
37. The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.
Lee SR; Yang DH; Ahn JS; Kim YK; Lee JJ; Choi YJ; Shin HJ; Chung JS; Cho YY; Chae YS; Kim JG; Sohn SK; Kim HJ
J Korean Med Sci; 2009 Jun; 24(3):498-503. PubMed ID: 19543516
[TBL] [Abstract][Full Text] [Related]
38. Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial.
Copland M; Slade D; McIlroy G; Horne G; Byrne JL; Rothwell K; Brock K; De Lavallade H; Craddock C; Clark RE; Smith ML; Fletcher R; Bishop R; Milojkovic D; Yap C
Lancet Haematol; 2022 Feb; 9(2):e121-e132. PubMed ID: 34906334
[TBL] [Abstract][Full Text] [Related]
39. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
Kaspers GJ; Zimmermann M; Reinhardt D; Gibson BE; Tamminga RY; Aleinikova O; Armendariz H; Dworzak M; Ha SY; Hasle H; Hovi L; Maschan A; Bertrand Y; Leverger GG; Razzouk BI; Rizzari C; Smisek P; Smith O; Stark B; Creutzig U
J Clin Oncol; 2013 Feb; 31(5):599-607. PubMed ID: 23319696
[TBL] [Abstract][Full Text] [Related]
40. De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG).
Ferrara F; Palmieri S; Pocali B; Pollio F; Viola A; Annunziata S; Sebastio L; Schiavone EM; Mele G; Gianfaldoni G; Leoni F
Eur J Haematol; 2002 Apr; 68(4):203-9. PubMed ID: 12071935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
